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Summary The combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN-a) has reported activity in the treatment of advanced colorectal
carcinoma. Laboratory studies of IFN-n suggest that this agent may offer theoretical advantages over IFN-a in combination with 5-FU. A total
of 27 patients with advanced or recurrent colorectal carcinoma were treated in a non-randomized open phase 11 study with a combination of
5-fluorouracil (750 mg m-1 daily for 5 days as a continuous intravenous (i.v.) infusion followed, from day 15, by i.v. bolus 750 mg m-2 every 7
days) and recombinant interferon-f [r-hlFN-P-1 a; 9 MIU (total dose) by subcutaneous injection from day 1 on every Monday, Wednesday and
Friday throughout the treatment period]. Toxicity was less than that seen with this schedule of 5-FU in combination with IFN-a. Among 21
evaluable patients, four objective responses were seen. Recombinant human interferon-beta-1 a in combination with 5-FU is an acceptable
regimen in terms of toxicity. However, the study did not demonstrate a superior response rate when compared with previous reports of
treatment with 5-FU alone or in combination with IFN-a.
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Five year survival from carcinoma of the colon and rectum is less
than 40%. Although 5-fluorouracil has been the mainstay ofpallia-
tive systemic therapy for advanced colorectal carcinoma for over
30 years, it is not curative in patients with metastatic disease. This
agent gives objective responses in less than 25% ofpatients when
used as a single agent, and there has been much interest in the
potential for modulating its effects. Several studies indicate that 5-
FU and IFN-a act in synergy to inhibit the growth of tumour cell
lines in vitro (Wadler and Schwartz, 1990), and in some clinical
studies this combination results in response rates (35-62%) higher
than that predicted for 5-FU alone (Pazdur et al, 1990; Wadler
and Wiernick, 1990; Wadler et al, 1991). However, this activity
has not been confirmed in other trials (Corfu-A Study Group,
1995; Hill et al, 1995)
Although IFN-,B has only 30% homology with interferon-a (de
Grado et al, 1982), it binds with greater affinity to certain
subclasses ofinterferon receptors (Ruzicka et al, 1987). In labora-
tory studies,r-hIFN-P-la exhibits greater antiproliferative activity
than IFN-a against some tumour cell lines (Borden et al, 1982)
and, against colorectal carcinoma cell lines, it demonstrates both
direct antiproliferative activity and synergy in combination with 5-
FU (Wong et al, 1989; Kase et al, 1993). In clinical phase II
studies, IFN-, was administered as a single agent to 32 patients
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in one patient (Lillis et al, 1987; Triozzi et al, 1987). This is similar
to the single-agent activity of IFN-a, which has been reported to
produce three responses among 66 patients (Kemeny and Younes,
1992). There is, therefore, a significant rationale for the testing of
IFN-P in combination with 5-FU in this patient group.
A phase II study examining the combination ofr-hIFN-p-1a and
5-FU was designed modelled on the 5-FU/IFN-a regimen of
Wadler et al (1990). In phase I studies ofr-hIFN-3-la, the dose of
9 MIU was identified as a tolerable dose of the interferon that
demonstrated immunomodulatory effects in vivo. This dose was
chosen for combination with 5-FU in a similar manner to that
described for IFN-a.
The aims ofthe study were to explore the efficacy ofthe combi-
nation of 5-FU with r-hIFN-p-la in patients with advanced
colorectal carcinoma and to evaluate the safety and tolerability of
the regimen in this patient group.
PATIENTS AND METHODS
Patients were recruited from the departments of Surgery and
Medical Oncology at St James's University Hospital. No patient
had received previous chemotherapy.
Patient eligibility
Patients were eligible if they had histologically confirmed adeno-
carcinoma of the colon or rectum with locally advanced or
metastatic disease not amenable to further surgery. Prior radiation
to specific sites was allowed, if non-irradiated, measurable sites
of evaluable disease remained. Patients were > 18 years of age,
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Table 1 Patient characteristics
Male/female 18/9
Age [median (range) years] 60 (42-82)
Karnofsky performance status
[median (range)] 80 (60-90)






performance status 2 60 (Karnofsky) and medically fit to receive
the trial medication, having normal haematological and biochem-
ical indices, unless due to the underlying disease. Patients gave
written consent according to the requirements ofthe local medical
research ethics committee.
Material
Recombinant human interferon-beta- 1a (Rebif), expressed in
mammalian cells with identical amino acid and carbohydrate
structure to natural human interferon-j, was supplied by Ares-
Serono, Geneva, Switzerland.
Treatment regimen
r-hIFN-,-la (9 MIU) was administered by subcutaneous injection
on day 1 and then each Monday, Wednesday and Friday for the
duration of the study period. 5-FU (750 mg m-2 day-') was given
by continuous intravenous infusion for 5 days from day 1 and then,
from day 15, 750 mg m-2 by i.v. bolus every 7 days. Doses were
modified in the event of haematological and other toxicities
according to a predetermined schedule.
Treatment was planned to continue for 6 months or until
progression, whichever occurred sooner. Maintenance with r-
hIFN-B-1a alone was allowed for patients who remained on treat-
ment for 6 months with stable disease (SD) or better at that time.
Monitoring and assessment
Pretreatment evaluation was made with serum chemistry,
including liver enzymes and carcinoembryonic antigen (CEA),
full blood count (FBC) and differential. Computerized tomog-
raphy (CT) of the abdomen and pelvis was performed in each
patient and plain radiography ofthe chest with chest CT, ifappro-
priate. FBC and chemistry were repeated at each chemotherapy
visit and tumour measurements repeated every 3 months during
the study period.
Responses reflect World Health Organization (WHO) defini-
tions: partial remission (PR) was defined as a decrease of evalu-
able tumour size (total two-dimensional area) of2 50% maintained
for 4 weeks; complete remission (CR) as complete disappearance
ofall known disease for at least 4 weeks; progressive disease (PD)
as a 25% or greater increase in the size of one or more measurable
lesions or the appearance of one or more new lesions; and stable
disease (SD) as failure to establish a 50% decrease or25% increase
in tumour volume. Patients were considered non-evaluable for
response, if they received less than 3 months of treatment with-
out documented progression of disease or were unavailable for
reassessment.
Table 2 A, Myelotoxicity; B, 5-FU-associated toxicity; C, other toxicities.
A
Patient group Neutropenia Neutropenia Neutropenia Neutropenia
grade I grade 11 grade III grade IV
(n=27) 5 (18) 4 (15) 4 (15) -
B+C
Toxicity Grade I Grade II Grade III Grade IV
B
Mucositis 8 (30) 2 (7) 1 (3) -
Diarrhoea 4 (15) 5 (18) 1 (3)
Plantar-palmar
inflammation 4 (15) 3 (11) -
Epistaxis 5 (18) - - -
CNS
(Cerebellar
syndrome) 1 (3) 1 (3) - -
C
Fatigue/malaise 9 (33) 6 (22) - -
Flu-like illness
rigors/fever 8 (30) 2 (7) 2 (7) -
Injection-site
reactions 6 (26) 7 (26) - -
Generalized rash 2 (7) 1 (3)
Nausea and/or
vomiting 10 (37) 5 (18) 2 (7) -
Anorexia 3 (11) - - -
Sore eyes 2 (7) - - -
Headaches 5 (18) - - -
Confusion 2 (7) - - -
Greatest toxicity experienced by n (%) patients. (Data in B and C are for
patients in both treatment groups)
RESULTS
A total of 27 patients were entered between January 1992 and
January 1993. The pretreatment characteristics of the patients are
shown in Table 1.
Treatment duration
Three patients died as a result of colorectal carcinoma within 30
days of starting treatment; none of the deaths were thought to be
related to treatment and progression was not documented after
entrance to the study: one patient suffered a haematemesis at day
12; one progressed rapidly between agreeing to take part in the
study and commencing treatment and would not have been treated
had he declined to withdraw; one patient was admitted to his local
hospice on day 30 where he died without full evaluation of the
cause. All three were of performance status 70 and with progres-
sive disease before treatment. Three further patients are not evalu-
able for response: one patient withdrew early owing to leucopenia
with infection on day 32 and declined further treatment; one
patient, aged 82, withdrew because of grade II nausea in week 3;
one patient was withdrawn (day 48) following a carotid throm-
bosis, thought to be unrelated to the treatment regimen. In all, 21
patients completed at least 3 months of treatment and are evalu-
able for response. All patients have been evaluated for toxicity.
The median duration of treatment was 18 weeks (range 1-76.5
weeks). Three patients continued both 5-FU and r-hIFN-0-la for
more than 6 months at their request, two with objective response
at 3 and 6 months and one with continuing stable disease at
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6 months. Only one patient received maintenance treatment with
r-hIFN-P-la alone. This patient had stable disease at 6 months and
received maintenance therapy for 2 months only.
Toxicity
In general, the regimen was well tolerated, although 14 patients
had dose modifications of 5-FU following toxic episodes (myelo-
suppression in six patients, stomatitis in one, diarrhoea in one,
plantar-palmar erythema in one, sepsis in one and a combination of
these factors in two patients) and treatment was delayed by 1 week
or more in 15 patients. The protocol allowed a delay in 5-FU until
grade 3 toxicities resolved followed by reintroduction at 66% of
the protocol dose. However, re-escalation of doses was allowed
and most patients experienced their dose delays and modifications
towards the end of treatment. Because of this, 5-FU was omitted
for only 28/492 weeks of treatment (for all patients) and dose
reductions occurred in only 24/492 weeks. Intended doses of5-FU
were administered in 440/492 (89%) oftreatment weeks.
Dose modifications of r-hIFN-,B-la were made in two patients
(myelosuppression in one patient, fatigue/flu-like illness in one
patient) and omitted from only 9/492 treatment weeks.
Myelotoxicity was generally acceptable. One patient required
intravenous antibiotic therapy for pyrexia associated with grade III
neutropenia. Neutrophil toxicity is shown in Table 2A. There was
no thrombocytopenia ofgreater than grade I and only two patients
experienced significant anaemia (all grade II).
Toxicities thought likely to be caused by the 5-FU component of
theregimen (Table 2B) were generally mild with few grade III orIV
toxicities seen. The CNS toxicity described in Table 2B was ofcere-
bellar in-coordination and thought most likely to be due to 5-FU.
Other toxicities that could not be ascribed directly to 5-FU
(Table 2C) were considered likely or possibly to be due to inter-
feron-f or the combination ofIFN/5-FU. Systemic effects such as
flu-like symptoms or rigors were generally of minor severity but
were experienced by nearly 50% of patients. A similar proportion
developed local reactions at the r-hIFN-P-1 a injection sites. In
many patients, the flu-like symptoms improved or became more
tolerable with continuing treatment, but injection-site reactions
worsened in some cases, with some patients experiencing 'recall'
phenomena at previous injection sites when new sites were
injected. In some patients who developed nausea and/or vomiting,
it was thought that the underlying disease was as likely as the
therapy to be responsible, but in all cases this symptom has been
recorded and attributed to the treatment regimen. Fifty-five percent
ofpatients complained oftiredness or general malaise. In the group
that experienced grade II fatigue/malaise, mean and median perfor-
mance status was no different to that of the entire treatment group
and so it is likely that this symptom was caused by the treatment.
Anti-tumour responses
Twenty-one patients were evaluable forresponse. Eleven progressed
on treatment (the three patients who died did not have documented
progression) and six patients had stable disease. Of those with SD,
one withdrew from the study because of toxicity and five patients
continued treatmentto at least 6 months. Ofthese five patients,three
had PD at 6 months, one patient progressed at 8 months after 2
months on interferon maintenance (following SD after 6 months of
combined therapy) and one progressed after 15 months of contin-
uous treatment with both agents. No patient with SD at 3 months
obtained an objective response with further treatment.
There were objective responses in four patients, all were docu-
mented after 3 months of treatment and all in liver metastases
(response rate in evaluable patients: 4/21, 19%; 95% CI 2-36%),
15% by 'intention to treat'. One patient with a solitary liver lesion
obtained a CR and relapsed at 21 months. A further patient with
extensive liver metastases obtained a partial remission maintained
for more than 24 months. These patients survived for more than 30
months. One patient obtained a PR lasting 10 months in the liver,
but had no response in a previously irradiated pelvic recurrence.
The fourthpatientresponded in the liverwith aPR at 3 months.The
liver metastases were not present at 6 months, but at the same time
there was progression ofpreviously stable disease in the pelvis.
Survival
The median survival for all patients was 8.4 months (95% CI
1.2-15.5 months). Patients who responded to therapy or who had
stable disease exhibited longer survival.
DISCUSSION
Metastatic and recurrent colorectal carcinoma is a relatively
chemoresistant tumour and treatment is palliative in intent. Recent
data suggest that patients who receive systemic chemotherapy may
have a better quality of life and may benefit in terms of overall
survival (Nordic Gastrointestinal Tumour Adjuvant Therapy
Group, 1992; Scheithauer et al, 1993). In this study, the response
rate was low, and survival for the group as a whole was less than
that reported in some other series. Responding patients demon-
strated prolonged survival compared with non-responders, as has
been demonstrated previously (Grafet al, 1994), but such observa-
tions must be interpreted cautiously. Our response rate of 4/27
(15%) patients and 19% (4/21) in evaluable patients is consistent
with previously reported response rates for 5-FU alone, but is also
similar to that seen in some studies of the Wadler regimen
(Kemeny et al, 1990; Kemeny and Younes, 1992) and is similar to
our own experience of a 15% response rate to a modified version
of that IFN-ct/5-FU combination (Pittman et al, 1993). Since the
reported response rates of 5-FU in combination with interferons
overlap those reported for 5-FU alone, results of randomized
studies are required to substantiate theproposition that this combi-
nation demonstrates significant synergy in vivo. A recent study
(Hill et al, 1995) failed to demonstrate a benefit of IFN-x in 106
patients randomized to receive the 5-FU regimen described in this
study with or without IFN-ax. Toxicity was significantly greater in
the IFN-ox-treated patients. Other randomized studies of5-FU with
or without IFN-a have been published in abstract form. In a study
of 161 patients (York et al, 1993), the combination of5-FU/IFN-at-
2a, given in the same manner as Wadler, obtained a higher
response rate than 5-FU alone [31%; (95% CI 21-43%) vs 19%
(11-30%)]. A significantly higher response rate of IFN-a/5-FU
over 5-FU alone (27% vs 10%, P = 0.04) has also been reported in
a study of 105 patients subjected to the same randomization
(Dufour et al, 1994). Significant benefits for the addition ofIFN-a,
however, were not seen in a randomized study when this agent was
combined with a protracted infusion of 5-FU (Findlay et al, 1994),
nor in the MRC study in which IFN-ax was administered to half of
260 patients receiving a combination of 5-FU and high-dose
leucovorin (Seymour et al, 1994). In each study, the addition of
IFN-x increased toxicity and no survival advantage for IFN-ca-
treated patients has been reported.
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In interpreting the data, it should be noted that the patients
recruited were ofarelatively poorperformance status, hadprogres-
sive disease and included previously treated patients. Because of
this, only 21 patients are evaluable for response. Additionally, the
study design did not include a randomization against a 5-FU-alone
treatment arm or a non-treatment arm, so interpretation of the
response rates and median survival must be made with caution.
The toxicities experienced by our patients were generally mild
and compare favourably with those experienced bypatients treated
with the Wadler IFN-ou5-FU combination (Wadler et al, 1989,
1991; Pazdur et al, 1990; Kemeny et al 1990; Kemeny and
Younes, 1992; Weh et al, 1992). With the exception of nausea and
vomiting [and local injection-site reactions (Table 2C), which are
not common with IFN-ax], this regimen resulted in similar grade
I/MI toxicities to the. combination of IFN-oc/5-FU. However,
patients treated with r-hIFN-13-la suffered less grade III/IV diar-
rhoea, stomatitis and CNS toxicity than those treated with IFN-x.
This may explain why fewerofourpatients required modifications
in the doses ofeither agent.
Since the response rate in this study is consistent with that seen
with IFN-oc/5-FU, conclusions cannot be drawn about the relative
efficacy of the IFN-ax and r-hIFN-p-la combinations. The rela-
tively poor performance status, previously treated patients may, in
some degree, explain the low response rate. Given the poorperfor-
mance status ofthis cohort, the withdrawal (because oftoxicity) of
only two patients, the low number of patients that required dose
modifications and the relative lack of grade III/IV toxicities, the
data suggest that this regimen may be better tolerated than 5-FU in
combination with IFN-a.
A recent preliminary report in abstract form (Villar et al, 1995)
suggests that the regimen described in this study may offer a
survival benefit compared with treatment with 5-FU alone. In the
study by Villar et al (1995), 48 patients were randomized to the
Wadler regimen of 5-FU with or withoutr-hIFN-p-Ia. No signifi-
cant difference was seen in response rates between the treatment
arms, but time to progression and overall survival are significantly
longer in patients who received r-hIFN-P-la. If this benefit is
maintained as the study matures, then the combination of 5-FU/r-
hIFN4 - Ia will require further evaluation in colorectal cancer.
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